Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2014 1
2015 2
2016 3
2017 1
2018 1
2019 2
2021 4
2022 3
2023 1
2024 2
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Pharmacological inhibition of the LIF/LIFR autocrine loop reveals vulnerability of ovarian cancer cells to ferroptosis.
Ebrahimi B, Viswanadhapalli S, Pratap UP, Rahul G, Yang X, Pitta Venkata P, Drel V, Santhamma B, Konda S, Li X, Sanchez ALR, Yan H, Sareddy GR, Xu Z, Singh BB, Valente PT, Chen Y, Lai Z, Rao M, Kost ER, Curiel T, Tekmal RR, Nair HB, Vadlamudi RK. Ebrahimi B, et al. NPJ Precis Oncol. 2024 May 24;8(1):118. doi: 10.1038/s41698-024-00612-y. NPJ Precis Oncol. 2024. PMID: 38789520 Free PMC article.
Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.
Collier AB, Viswanadhapalli S, Gopalam R, Lee TK, Kassees K, Parra K, Sharma G, Reese TC, Liu X, Yang X, Ebrahimi B, Pratap UP, Mahajan M, Arnold WC, Baker A, Chen CY, Elmore ST, Subbarayalu P, Sareddy GR, Valente PT, Kost ER, Ahn JM, Vadlamudi RK. Collier AB, et al. Among authors: ebrahimi b. Cancers (Basel). 2024 Jan 24;16(3):500. doi: 10.3390/cancers16030500. Cancers (Basel). 2024. PMID: 38339252 Free PMC article.
Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis.
Romo B, Fuentes Z, Randolph L, Mahajan M, Aller EJ, Ebrahimi B, Santhamma B, Pratap UP, Subbarayalu P, Nagandla H, Thomas C, Nair HB, Vadlamudi RK, Viswanadhapalli S. Romo B, et al. Among authors: ebrahimi b. Cancers (Basel). 2025 Feb 25;17(5):790. doi: 10.3390/cancers17050790. Cancers (Basel). 2025. PMID: 40075639 Free PMC article.
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK. Altwegg KA, et al. Among authors: ebrahimi b. Cancer Res. 2022 Oct 17;82(20):3830-3844. doi: 10.1158/0008-5472.CAN-22-0698. Cancer Res. 2022. PMID: 35950923 Free PMC article.
25 results